ViiV Says Latest Data Back Two-Drug Approach, Plans Year-End Fostemsavir Filing

ViiV Healthcare research head tells Scrip she expects Dovato’s latest data presentation should boost the two-drug regimen’s uptake, and that the AIDS-fighter plans a US FDA filing of its investigational candidate fostemsavir before end-2019 following good Phase III BRIGHTE results.

HIV virus
Dovato and fostemsavir Data presented at International AIDS Society Meeting in Mexico • Source: Shutterstock

GlaxoSmithKline PLC’s HIV medicines unit ViiV Healthcare , which represents about 20% of GSK's sales, believes its two-drug therapy Dovato (dolutegravir/lamivudine) will see better acceptance and a boost in its sales following positive data presented at this week’s International AIDS Society meeting in Mexico City.

And good results also presented at the AIDS conference from ViiV’s Phase III BRIGHTE study demonstrated strong efficacy of investigational...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip